SCHEMBL12279136

SCHEMBL12279136

CNC(=N)NCCC[C@@H](N)C(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.41
OTC P00480 1/20 0.37
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36
GNAI1 P63096 1/20 0.36
RRM1 P23921 1/20 0.35
KISS1R Q969F8 1/20 0.34
ANPEP P15144 2/20 0.33
RNPEP Q9H4A4 2/20 0.33
DNPEP Q9ULA0 1/20 0.33
DDAH1 O94760 1/20 0.33
NOS3 P29474 2/20 0.33
NOS1 P29475 2/20 0.33
NOS2 P35228 2/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32
HIF1A Q16665 1/20 0.32
PAOX Q6QHF9 2/20 0.32
MEN1 O00255 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17995247 1.00 DPP7 (0.41) DPP7OTCGNAI3GNAO1GNAI1
Tilarginine SCHEMBL1321022 0.87 OTC (0.49) DPP7OTCDDAH1NOS3NOS1
Tilarginine SCHEMBL6370536 0.86 OTC (0.51) DPP7OTCDDAH1NOS3NOS1
SCHEMBL19608041 0.86 DPP7 (0.41) DPP7OTCGNAI3GNAO1GNAI1
Tilarginine SCHEMBL12028766 0.86 OTC (0.51) DPP7OTCDDAH1NOS3NOS1
Tilarginine SCHEMBL315843 0.86 OTC (0.51) DPP7OTCDDAH1NOS3NOS1
Tilarginine SCHEMBL2229626 0.85 OTC (0.50) DPP7OTCDDAH1NOS3NOS1
SCHEMBL18542868 0.84 DPP7 (0.44) DPP7OTCGNAI3GNAO1GNAI1
SCHEMBL18542869 0.84 DPP7 (0.44) DPP7OTCGNAI3GNAO1GNAI1
SCHEMBL19368710 0.84 DPP7 (0.44) DPP7OTCGNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3311823-B1 METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS SYNEDGEN INC (US) 2020-11-25 EP disclosed
EP-2555760-B1 CHITOSAN DERIVATIVES FOR THE TREATMENT OF MUCOSITIS OR ULCERATION SYNEDGEN INC (US) 2019-10-16 EP disclosed
US-20130190227-A1 CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH SYNEDGEN, INC. (US) 2013-07-25 US disclosed
WO-2011127144-A1 METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS SYNEDGEN INC. (US) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190227-A1 CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH CHIT1, CHIA, ALG1 DPP7 461/4885OTC 428/4885GNAI3 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.